L92.2
Granuloma faciale [eosinophilic granuloma of skin]
Clinical Classification Guidelines
Medical Intelligence & Overview
Granuloma faciale is a rare, benign skin condition characterized by the appearance of reddish-brown, oval or elongated plaques on the face. This condition, also known as eosinophilic granuloma of the skin, typically develops slowly over time and primarily affects adults. Although the exact cause is unknown, it is considered a localized inflammatory reaction involving immune cells. Despite its persistent nature, granuloma faciale is not cancerous and does not pose a serious health threat. Management often involves topical treatments, but the condition may require ongoing care due to its chronic nature.
Causes & Symptoms
Clinical Causes: Unknown exact triggers, but believed to involve immune system abnormalities Possible local immune response to unidentified factors No clear link to infections, allergens, or systemic diseases Genetic predisposition is not well established Environmental factors are not definitively linked
Key Symptoms: Red or reddish-brown nodules or plaques on the face Lesions often have a smooth or slightly shiny surface Lesions typically appear on the cheeks, nose, or forehead Possible presence of telangiectasias (small visible blood vessels) within the lesions Lesions may be asymptomatic, but some might be tender or cause slight itching Persistent lesions that tend to resist spontaneous resolution Typically, lesions do not ulcerate or drain
Diagnostic & Treatment
Diagnosis Path: Diagnosis is primarily based on clinical examination followed by a skin biopsy. The biopsy reveals a dense infiltrate of eosinophils and other immune cells within the skin, along with characteristic features such as a Grenz zone—an area of normal skin separating the lesion from the epidermis. Additional tests may be performed to rule out other skin conditions with similar appearances, such as granulomatous diseases or skin cancers. Imaging is generally not required for diagnosis. A dermatologist evaluates the findings to confirm the diagnosis and determine the most appropriate management approach.
Treatment Protocols: Treatment options aim to reduce the appearance of the lesions and manage symptoms, although complete resolution can be challenging. Common strategies include: - Topical corticosteroids to reduce inflammation - Topical or intralesional corticosteroid injections for more stubborn lesions - Topical calcineurin inhibitors, such as tacrolimus, as an alternative - Cryotherapy, laser therapy, or dermatological procedures to remove or diminish the lesions - Systemic treatments are rarely used but may be considered in resistant cases Long-term follow-up is often necessary as lesions may recur or persist despite therapy. Since the condition is benign, treatment plans are tailored to the patient’s cosmetic concerns and overall health status.
Clinical Advice & FAQs
Billing Guidance
Is L92.2 a billable ICD-10 code?
Yes, L92.2 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report L92.2?
Clinical documentation must specify the nature of Granuloma faciale [eosinophilic granuloma of skin] and any associated comorbidities for accurate reporting.
Cite this Clinical Reference